BioArctic AB (publ)'s (NASDAQ STOCKHOLM: BIOA B) partner Eisai announced today that the subcutaneous autoinjector formulation of Leqembi (known as Leqembi Pen in Japan) has been approved as a new ...

The First and Only Anti-Amyloid Treatment in Japan that Enable At-Home Administration for Alzheimer's Disease, a Progressive ...

Subcutaneous administration of tarlatamab was well tolerated and demonstrated preliminary antitumor activity in patients with ...

Japan has approved the LEQEMBI Pen subcutaneous autoinjector for early Alzheimer’s disease, enabling once-weekly administration at home by patients or care partners.

Subcutaneous administration of tarlatamab was well tolerated and demonstrated preliminary antitumor activity in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC), ...

Sandoz is offering treprostinil injection for subcutaneous administration to treat patients diagnosed with pulmonary arterial hypertension. Sandoz treprostinil injection was the first generic of ...

The subcutaneous administration of granisetron, an antiemetic pharmaceutical drug (suitable for control of vomiting), achieves similar blood concentrations to those administered intravenously. This ...

Please provide your email address to receive an email when new articles are posted on . Patients can use subcutaneous lecanemab during the 18-month initiation period. Symptoms were stable for 72.5% of ...

Monash University researchers, alongside key partner Halozyme Therapeutics, report findings in support of shifting the way anti-cancer immunotherapy is administered from intravenous administration to ...

- Study results also indicated overall similar safety profile with differences in incidence of peripheral neuropathy - CAMBRIDGE, Mass., January 23, 2012-Millennium: The Takeda Oncology Company with ...

The gastric hormone ghrelin appears a useful agent to stimulate food intake in people with anorexia of illness. The loss of ghrelin's acyl group renders it inactive, thus it has been thought that ...

Pen", the subcutaneous (SC) formulation of the anti-amyloid beta (AB) protofibril antibody "LEQEMBI(R)" (brand name, generic name: lecanemab) has been approved in Japan as a new route of ...